Related Experiment Video
Updated: Jul 20, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
LncRNA PVT1: as a therapeutic target for breast cancer
Kamilya Jamel Baljon1, Pushpamala Ramaiah2, Ebraheem Abdu Musad Saleh3
1Faculty of Nursing, Umm al, Qura University,Makkah, Saudi Arabia.
Abstract:
A significant number of women are identified with breast cancer (BC) every year, making it among the most prevalent malignancies and one of the leading causes of mortality globally. Despite significant progress in understanding BC pathogenesis and treatment options, there is still a need to identify new therapeutic targets and develop more effective treatments. LncRNAs have been discovered as biomarkers and a promising target for various cancers, including BC. PVT1 is a particular one of these lncRNAs, and research has indicated that it has a significant impact on the appearance and progression of BC.PVT1 is an attractive therapeutic target for BC due to its role in promoting cancer cell growth, metastasis and invasion. In addition to its potential as a treatment strategy, PVT1 may also have diagnostic value in BC. In this article, we will discuss targeting PVT1 as a treatment strategy for BC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
MicroRNAs
Abnormal Proliferation
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

